Instructions for OVANELIYA (Estriol) vaginal suppositories 0,5 mg 15 pcs
Release form
Rectal suppositories
Description:
Rectal suppositories are white to yellowish-white in colour and are torpedo shaped and have no visible impurities and heterogeneities; an air rod and/or a funnel depression is allowed on the longitudinal section.
1 sp.
Estriol 0.5 mg
Auxiliary substances: vitepsol S58 - 2499.5 mg.
5 pcs. - packages of box contour (2) - cardboard packs.
5 pcs. - box-type contour (3) packages - cardboard packs.
5 pcs. - box-type contour (4) packages - cardboard packs.
ATC codes
G03CA04 Estriol
Clinical-pharmacological groups / Group affiliation
Estrogen preparation
Active substance
Estriol
Pharmacotherapy group
Estrogen
Testimony OVANELIYA:
CGT for the treatment of lower urinary and genital tract atrophy associated with estrogenic failure; Pre- and post-operative treatment of postmenopausal women with vaginal access; For diagnostic purposes with unclear results of cytological examination of the cervix (suspicion of the tumour process) against the background of atrophic changes.
Method of use, course and dosage Estriol:
Intravaginally administered. The dose is 500 ug/day. The application procedure is set individually, depending on the indications and clinical situation.
Nosology (ICD codes)
N95.1
Menopause and Menopause in Women
N95.2
Postmenopausal atrophic vaginitis
N95.3
Conditions associated with artificially induced menopause
Z03
Medical observation and evaluation in the case of suspected disease or pathological condition
Z51.4
Preparatory procedures for follow-up treatment or examination not classified elsewhere
Pharmacological effect OVANELIYA:
Estrogen, an analog of the natural female hormone. Replenishes estrogen deficiency in postmenopausal women and relieves postmenopausal symptoms. It is most effective in the treatment of urinary disorders. In the atrophic mucosa of the lower urinary tract, Estriol promotes the normalization of urinary tract epithelium and contributes to the restoration of normal microflora and physiological pH in the vagina. The invention makes it possible to increase the resistance of epithelial cells of the genitourinary tract to infections and inflammation, thereby reducing complaints such as pain during sexual intercourse, dryness and itching in the vagina, to reduce the probability of vaginal infections and urinary tract infections, to normalise urination and to prevent urinary incontinence.
Unlike other estrogens, Estriol has a short period of action, as in the endometrial cell nuclei it is held for a short period of time. It is assumed that a single daily dose does not cause endometrial proliferation. Therefore, there is no need for cyclic progestagen administration and no withdrawal bleeding. Furthermore, estriol is shown not to increase mammographic density.
